Healthcare provider profile · identity verified

Hailon Wong

Family Practice · FORT MYERS, FL · NPI 1194189852

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	299	142
Amlodipine Besylate	Amlodipine Besylate	186	81
Lisinopril	Lisinopril	144	63
Albuterol Sulfate Hfa	Albuterol Sulfate	123	44
Pantoprazole Sodium	Pantoprazole Sodium	119	58
Losartan Potassium	Losartan Potassium	106	52
Gabapentin	Gabapentin	105	49
Levothyroxine Sodium	Levothyroxine Sodium	104	43
Metoprolol Succinate	Metoprolol Succinate	77	37
Ozempic	Semaglutide	77	32
Rosuvastatin Calcium	Rosuvastatin Calcium	72	36
Metformin Hcl	Metformin Hcl	68	36
Fluticasone Propionate	Fluticasone Propionate	67	39
Ezetimibe	Ezetimibe	65	22
Carvedilol	Carvedilol	59	23
Eliquis	Apixaban	59	24
Metoprolol Tartrate	Metoprolol Tartrate	58	23
Omeprazole	Omeprazole	57	27
Tamsulosin Hcl	Tamsulosin Hcl	57	24
Hydrochlorothiazide	Hydrochlorothiazide	49	27
Jardiance	Empagliflozin	48	23
Spironolactone	Spironolactone	43	18
Metformin Hcl Er	Metformin Hcl	42	21
Fluoxetine Hcl	Fluoxetine Hcl	39	16
Escitalopram Oxalate	Escitalopram Oxalate	36	21
Furosemide	Furosemide	36	19
Sertraline Hcl	Sertraline Hcl	35	19
Chlorthalidone	Chlorthalidone	34	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	15
Simvastatin	Simvastatin	31	14
Clopidogrel	Clopidogrel Bisulfate	30	17
Famotidine	Famotidine	29	15
Ketoconazole	Ketoconazole	29	14
Potassium Chloride	Potassium Chloride	29	suppressed
Mounjaro	Tirzepatide	28	12
Propranolol Hcl	Propranolol Hcl	28	12
Trazodone Hcl	Trazodone Hcl	28	13
Citalopram Hbr	Citalopram Hydrobromide	26	14
Diclofenac Sodium	Diclofenac Sodium	26	18
Prednisone	Prednisone	26	22
Duloxetine Hcl	Duloxetine Hcl	25	16
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Allopurinol	Allopurinol	24	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	11
Torsemide	Torsemide	23	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Baclofen	Baclofen	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	12
Buspirone Hcl	Buspirone Hcl	20	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	11
Ibuprofen	Ibuprofen	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Acyclovir	Acyclovir	17	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	11
Finasteride	Finasteride	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	13
Enalapril Maleate	Enalapril Maleate	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Estradiol	Estradiol	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Varenicline Tartrate	Varenicline Tartrate	12	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error